The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics
Open accessAbstract
The Bill and Melinda Gates Foundation supports an ambitious portfolio of novel vaccines, drug regimens, and diagnostic tools for tuberculosis (TB). We elicited the expected efficacies and improvements of the novel interventions in discussions with the foundations managing their development. Using an age-structured mathematical model of TB, we explored the potential benefits of novel interventions under development and those not yet in the portfolio, focusing on the WHO Southeast Asia region. Neonatal vaccination with the portfolio vaccine decreases TB incidence by 39% to 52% by 2050. Drug regimens that shorten treatment duration and are efficacious against drug-resistant strains reduce incidence by 10–27%. New diagnostics reduce incidence by 13–42%. A triple combination of a portfolio vaccine, drug regimen, and diagnostics reduces incidence by 71%. A short mass vaccination catch-up campaign, not yet in the portfolio, to augment the triple combination, accelerates the decrease, preventing >30% more cases by 2050 than just the triple combination. New vaccines and drug regimens targeted at the vast reservoir of latently infected people, not in the portfolio, would reduce incidence by 37% and 82%, respectively. The combination of preventive latent therapy and a 2-month drug treatment regimen reduces incidence by 94%. Novel technologies in the pipeline would achieve substantial reductions in TB incidence, but not the Stop TB Partnership target for elimination. Elimination will require new delivery strategies, such as mass vaccination campaigns, and new products targeted at latently infected people.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Numerical recipes in C: the art of scientific computing
(1993) · Choice Reviews Online · doi:10.5860/choice.30-5638 · Cited by 17,933
Numerical Recipes in C-The Art of Scientific Computing.
G., W., Press, W. H., Flannery, B. P., Teukolsky, S. A., & Vetterling, W. T. (1989) · Mathematics of Computation · doi:10.2307/2008673 · Cited by 1,513
Small, P. M., Hopewell, P. C., Singh, S. P., Paz, A., Parsonnet, J., Ruston, D. C., Schecter, G. F., Daley, C. L., & Schoolnik, G. K. (1994) · New England Journal of Medicine · doi:10.1056/nejm199406163302402 · Cited by 1,111
Controlled chemoprophylaxis trials in tuberculosis. A general review.
Sh, F. (1970) · PubMed · Cited by 721
Global tuberculosis control: surveillance planning financing. WHO report 2008.
Dye, C., Floyd, K., & Uplekar, M. (2008) · Cited by 575
Self-citationVYNNYCKY, E., & FINE, P. E. M. (1997) · Epidemiology and Infection · doi:10.1017/s0950268897007917 · Cited by 555
[Epidemiology of tuberculosis].
Neumann, G. (1971) · PubMed · Cited by 523
The early bactericidal activity of drugs in patients with pulmonary tuberculosis.
Jindani, A., Aber, V. R., Edwards, E. A., & Mitchison, D. A. (1980) · PubMed · doi:10.1164/arrd.1980.121.6.939 · Cited by 487
The intrinsic transmission dynamics of tuberculosis epidemics
Blower, S. M., Mclean, A. R., Porco, T. C., Small, P. M., Hopewell, P. C., Sanchez, M. A., & Moss, A. R. (1995) · Nature Medicine · doi:10.1038/nm0895-815 · Cited by 471
Cited by
The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling
Houben, R. M. G. J., & Dodd, P. J. (2016) · PLOS Medicine · doi:10.1371/journal.pmed.1002152 · Cited by 2,054
Lewinsohn, D. M., Leonard, M. K., LoBue, P. A., Cohn, D. L., Daley, C. L., Desmond, E., Keane, J., Lewinsohn, D. A., Loeffler, A. M., Mazurek, G. H., et al. (2017) · Clinical Infectious Diseases · doi:10.1093/cid/ciw694 · Cited by 992
“As described by Abu-Raddad et al [241], improved detection of those with TB and improved identification of those at risk to progress once infected have the potential to substantially decrease the prevalence of TB and its associated mortality.”
MethodTuberculosis control and elimination 2010–50: cure, care, and social development
Lönnroth, K., Castro, K. G., Chakaya, J. M., Chauhan, L. S., Floyd, K., Glaziou, P., & Raviglione, M. C. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60483-7 · Cited by 899
The Population Dynamics and Control of Tuberculosis
Dye, C., & Williams, B. G. (2010) · Science · doi:10.1126/science.1185449 · Cited by 604
Self-citationRoy, A., Eisenhut, M., Harris, R. J., Rodrigues, L. C., Sridhar, S., Habermann, S., Snell, L., Mangtani, P., Adetifa, I., Lalvani, A., et al. (2014) · BMJ · doi:10.1136/bmj.g4643 · Cited by 588
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Dorman, S. E., Nahid, P., Kurbatova, E. V., Phillips, P. P. J., Bryant, K., Dooley, K. E., Engle, M., Goldberg, S. V., Phan, H. T. T., Hakim, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2033400 · Cited by 539
Sterling, T. R., Njie, G., Zenner, D., Cohn, D. L., Reves, R., Ahmed, A., Menzies, D., Horsburgh, C. R., Crane, C. M., Burgos, M., et al. (2020) · MMWR. Recommendations and Reports · doi:10.15585/mmwr.rr6901a1 · Cited by 495
Overcoming barriers to patient adherence: the case for developing innovative drug delivery systems
Baryakova, T. H., Pogostin, B. H., Langer, R., & McHugh, K. J. (2023) · Nature Reviews Drug Discovery · doi:10.1038/s41573-023-00670-0 · Cited by 492
Lawn, S. D., & Nicol, M. P. (2011) · Future Microbiology · doi:10.2217/fmb.11.84 · Cited by 486
Immunological biomarkers of tuberculosis
Walzl, G., Ronacher, K., Hanekom, W., Scriba, T. J., & Zumla, A. (2011) · Nature Reviews Immunology · doi:10.1038/nri2960 · Cited by 477
Biomarkers and diagnostics for tuberculosis: progress, needs, and translation into practice
Wallis, R. S., Pai, M., Menzies, D., Doherty, T. M., Walzl, G., Perkins, M. D., & Zumla, A. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-5 · Cited by 453
Diacon, A. H., Dawson, R., von Groote-Bidlingmaier, F., Symons, G., Venter, A., Donald, P. R., van Niekerk, C., Everitt, D., Winter, H., Becker, P., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61080-0 · Cited by 435
Suthar, A. B., Lawn, S. D., del Amo, J., Getahun, H., Dye, C., Sculier, D., Sterling, T. R., Chaisson, R. E., Williams, B. G., Harries, A. D., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001270 · Cited by 402
Self-citationGlobal tuberculosis drug development pipeline: the need and the reality
Ma, Z., Lienhardt, C., McIlleron, H., Nunn, A. J., & Wang, X. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60359-9 · Cited by 374
After 2015: infectious diseases in a new era of health and development
Dye, C. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0426 · Cited by 361
Self-citationWhat We Know About Tuberculosis Transmission: An Overview
Churchyard, G., Kim, P., Shah, N. S., Rustomjee, R., Gandhi, N., Mathema, B., Dowdy, D., Kasmar, A., & Cardenas, V. (2017) · The Journal of Infectious Diseases · doi:10.1093/infdis/jix362 · Cited by 341
The ongoing challenge of latent tuberculosis
Esmail, H., Barry, C. E., Young, D. B., & Wilkinson, R. J. (2014) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2013.0437 · Cited by 325
Kaufmann, S. H., Hussey, G., & Lambert, P.-H. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60393-5 · Cited by 299
Diel, R., Loddenkemper, R., & Nienhaus, A. (2012) · Chest · doi:10.1378/chest.11-3157 · Cited by 282
Arbues, A., Aguilo, J. I., Gonzalo-Asensio, J., Marinova, D., Uranga, S., Puentes, E., Fernandez, C., Parra, A., Cardona, P. J., Vilaplana, C., et al. (2013) · Vaccine · doi:10.1016/j.vaccine.2013.07.051 · Cited by 256
Tuberculosis Vaccines and Prevention of Infection
Hawn, T. R., Day, T. A., Scriba, T. J., Hatherill, M., Hanekom, W. A., Evans, T. G., Churchyard, G. J., Kublin, J. G., Bekker, L.-G., & Self, S. G. (2014) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.00021-14 · Cited by 164
Novel approaches to tuberculosis vaccine development
Kaufmann, S. H. E., Weiner, J., & von Reyn, C. F. (2017) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2016.10.018 · Cited by 160
Li, X., Yang, Y., Zhou, F., Zhang, Y., Lu, H., Jin, Q., & Gao, L. (2011) · PLoS ONE · doi:10.1371/journal.pone.0015831 · Cited by 126
Scientific advances and the end of tuberculosis: a report from the Lancet Commission on Tuberculosis
Reid, M., Agbassi, Y. J. P., Arinaminpathy, N., Bercasio, A., Bhargava, A., Bhargava, M., Bloom, A., Cattamanchi, A., Chaisson, R., Chin, D., et al. (2023) · The Lancet · doi:10.1016/s0140-6736(23)01379-x · Cited by 87
Contact Tracing of Tuberculosis: A Systematic Review of Transmission Modelling Studies
Begun, M., Newall, A. T., Marks, G. B., & Wood, J. G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0072470 · Cited by 52
Rapid Diagnosis of Pediatric Mycobacterial Lymphadenitis Using Fine Needle Aspiration Biopsy
Coetzee, L., Nicol, M. P., Jacobson, R., Schubert, P. T., van Helden, P. D., Warren, R. M., & Wright, C. A. (2014) · Pediatric Infectious Disease Journal · doi:10.1097/inf.0000000000000312 · Cited by 29
Metadata
- Authors
- Abu-Raddad, L. J., Sabatelli, L., Achterberg, J. T., Sugimoto, J. D., Longini, I. M., Dye, C., & Halloran, M. E.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2009-08-18
- Volume
- 106
- Issue
- 33
- Pages
- 13980-13985
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2047509792
- Cited by
- 348
- References
- 37
- FWCI
- 16.75
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.